NiKang Therapeutics


Clinical-stage biotechnology company focused on discovery and development of small-molecule oncology therapeutics. Uses disease-biology-driven target selection and structure-based drug design to address difficult-to-drug targets and has advanced multiple small molecules into first-in-human clinical testing.

Industries

Biotechnology
Health Care
Medical
Oncology
Biotechnology Research

Nr. of Employees

medium (51-250)

NiKang Therapeutics

Wilmington, Delaware, United States


Patents

Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof

US-12415779-B2

View Details

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

US-12391642-B2

View Details

Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors

US-12264167-B2

View Details

2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors

US-12171741-B2

View Details

Indane derivatives as hypoxia inducible factor-2(α) inhibitors

US-12077506-B2

View Details

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

US-11753366-B2

View Details
View All Patents

Products

NKT2152

Orally available small-molecule inhibitor targeting HIF2α discovered by structure-based design; demonstrated tumor growth inhibition in multiple solid tumor xenograft models and evaluated in Phase 1/2 studies.

NKT3964

First-in-class, orally bioavailable PROTAC degrader designed for selective degradation of CDK2; evaluated in Phase 1 clinical studies for advanced or metastatic solid tumors.

NKT5097

First-in-class, orally bioavailable dual degrader targeting CDK2 and CDK4 designed to simultaneously inhibit CDK2 and CDK4 pathways; under clinical evaluation as single agent and in combination with endocrine therapy.

Expertise Areas

  • Oncology small-molecule drug discovery
  • Structure-based drug design
  • PROTAC degrader development
  • Translational research and biomarker-driven patient stratification
  • Show More (3)

Key Technologies

  • Structure-based drug design
  • PROTAC (targeted protein degradation)
  • Oral small-molecule therapeutics
  • In vivo xenograft models
  • Show More (3)

News & Updates

Presentation of a CDK2/4 dual degrader for cancer therapy and supporting data presented at SABCS 2025; press release distributed via Business Wire.

Company announced completion of dosing of the first cohort in a Phase 1 study of a CDK2/4 dual degrader; press release on Business Wire.

Company completed dosing of the first cohort in a Phase 1 study of a CDK2 PROTAC degrader; press release on Business Wire.

Announcement of first patient dosed in a Phase 1b/2 combination study evaluating an HIF2α inhibitor with standard-of-care for hepatocellular carcinoma; press release on Business Wire.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.